Showing 7 posts of 7 posts found.


Sandoz shares positive results from MYLIGHT phase 3 study

August 16, 2023
Research and Development Opthalmology, Sandoz, aflibercept, clinical trial, wet macular degeneration

Sandoz has announced positive results from the phase 3 MYLIGHT confirmatory efficacy and safety study for its biosimilar aflibercept, for …

Bayer image

Bayer and Regeneron eye drug gains another indication

March 26, 2015
Sales and Marketing Bayer, Eylea, FDA, Japan, Lucentis, MRI, Regeneron, aflibercept

Bayer and Regeneron’s Eylea has added to a growing list of indications with its new approval to treat a type …

Baye image

New EU indication for Bayer and Regeneron eye drug

February 27, 2015
Sales and Marketing Bayer, European Commission, Eylea, aflibercept

Bayer and Regeneron’s Eylea is now indicated for every type of the eye disease retinal vein occlusion (RVO) thanks to …

Bayer image

New drugs give Bayer record sales

February 26, 2015
Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo

Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …

NHS drops 25 treatments from Cancer Drugs Fund

January 12, 2015
Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus

Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …

Bayer eye drug succeeds in long-term study

February 21, 2012
Research and Development, Sales and Marketing Bayer, Lucentis, aflibercept, wet AMD

Bayer’s eye drug aflibercept has succeeded in a long-term study in patients with a common eye condition.  The Phase III …

Sanofi lung cancer drug fails in late-stage trial

March 11, 2011
Research and Development Cancer, NSCLC, Regeneron, Sanofi-Aventis, aflibercept, non-small cell lung cancer

Sanofi-Aventis’ lung cancer drug aflibercept has failed to meet its primary endpoint in a phase III trial. The late-stage VITAL …

Latest content